SREBF2 and obstructive sleep apnea syndrome: The mechanisms underlying OSA risk may be modulated by SREBP2—miR-210—induced mitochondrial dysfunction in endothelial cells (ECs), providing compelling evidence that miR-210 may be a suitable candidate as an OSA biomarker and a therapeutic target for interventional studies (166).